Latest Epoetin beta Stories
Correcting anemia, a red blood cell deficiency, can preserve kidney function in many kidney transplant recipients.
Use of erythropoiesis-stimulating agents is associated with an increased risk of venous thromboembolism.
Cancer patients find themselves in a sort of catch-22 situation when it comes to treating the anemia common in people with the disease.
The use of drugs to encourage red blood cell formation (erythropoiesis-stimulating agents) in cancer patients with anemia increases the risk of death and serious adverse events such as blood clots, found a new study in CMAJ.
Affymax, a biopharmaceutical company, has announced positive results from a long-term safety and effectiveness study of its lead investigational therapy, Hematide, which is being evaluated for the treatment of anemia in chronic renal failure patients.
Affymax, a biopharmaceutical company, has completed enrollment in the second of four Phase III clinical trials of its lead investigational therapy, Hematide, which is being evaluated for the treatment of anemia in chronic renal failure patients.
Affymax, Inc. (Nasdaq:AFFY) today announced that enrollment has begun in a Phase 2 clinical trial of Hematide(TM) to correct anemia in patients with chronic renal failure (CRF) who are undergoing dialysis and are not actively being treated with an erythropoiesis stimulating agent (ESA).
By Cornes, Paul; Coiffier, Bertrand; Zambrowski, J
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.